196 related articles for article (PubMed ID: 32138807)
21. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
22. S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma.
Reeb AN; Li W; Sewell W; Marlow LA; Tun HW; Smallridge RC; Copland JA; Spradling K; Chernock R; Lin RY
J Clin Endocrinol Metab; 2015 Feb; 100(2):E232-42. PubMed ID: 25423568
[TBL] [Abstract][Full Text] [Related]
23. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
[TBL] [Abstract][Full Text] [Related]
24. The Role of Notch1 Signaling in Anaplastic Thyroid Carcinoma.
Kim HJ; Kim MJ; Kim A; Jung CW; Park S; Koh JS; Myung JK
Cancer Res Treat; 2017 Apr; 49(2):509-517. PubMed ID: 27586674
[TBL] [Abstract][Full Text] [Related]
25. Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin.
Pan Y; Liu P; Chen D; Dou L
Cancer Biomark; 2017; 18(4):357-366. PubMed ID: 28128736
[TBL] [Abstract][Full Text] [Related]
26. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
[TBL] [Abstract][Full Text] [Related]
27.
Yang J; Jiang X; Chen Y; Teng L
Discov Med; 2023 Dec; 35(179):1167-1176. PubMed ID: 38058082
[TBL] [Abstract][Full Text] [Related]
28. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy.
Huang PY; Zeng TT; Ban X; Li MQ; Zhang BZ; Zhu YH; Hua WF; Mai HQ; Zhang L; Guan XY; Li Y
BMC Cancer; 2016 Aug; 16(1):669. PubMed ID: 27549330
[TBL] [Abstract][Full Text] [Related]
29. Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression.
Wang FW; Cai MY; Mai SJ; Chen JW; Bai HY; Li Y; Liao YJ; Li CP; Tian XP; Kung HF; Guan XY; Xie D
Oncotarget; 2014 Aug; 5(16):6716-33. PubMed ID: 25071013
[TBL] [Abstract][Full Text] [Related]
30. Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma.
Yang H; Li XD; Zhou Y; Ban X; Zeng TT; Li L; Zhang BZ; Yun J; Xie D; Guan XY; Li Y
Oncotarget; 2015 Sep; 6(28):26079-89. PubMed ID: 26317793
[TBL] [Abstract][Full Text] [Related]
31. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
32. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation.
Chang JW; Kang SU; Choi JW; Shin YS; Baek SJ; Lee SH; Kim CH
Free Radic Biol Med; 2014 Feb; 67():115-30. PubMed ID: 24216474
[TBL] [Abstract][Full Text] [Related]
33. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
[TBL] [Abstract][Full Text] [Related]
34. Overexpressed in anaplastic thyroid carcinoma-1 (OEATC-1) as a novel gene responsible for anaplastic thyroid carcinoma.
Mizutani K; Onda M; Asaka S; Akaishi J; Miyamoto S; Yoshida A; Nagahama M; Ito K; Emi M
Cancer; 2005 May; 103(9):1785-90. PubMed ID: 15789362
[TBL] [Abstract][Full Text] [Related]
35. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
von Roemeling CA; Marlow LA; Pinkerton AB; Crist A; Miller J; Tun HW; Smallridge RC; Copland JA
J Clin Endocrinol Metab; 2015 May; 100(5):E697-709. PubMed ID: 25675381
[TBL] [Abstract][Full Text] [Related]
36. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
37. Targeting TGF-β1 and AKT signal on growth and metastasis of anaplastic thyroid cancer cell in vivo.
Li Y; Chen D; Hao FY; Zhang KJ
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2581-7. PubMed ID: 27383308
[TBL] [Abstract][Full Text] [Related]
38. MiR-200 Regulates Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer via EGF/EGFR Signaling.
Xue L; Su D; Li D; Gao W; Yuan R; Pang W
Cell Biochem Biophys; 2015 May; 72(1):185-90. PubMed ID: 25542369
[TBL] [Abstract][Full Text] [Related]
39. Long noncoding RNA UCA1 promotes anaplastic thyroid cancer cell proliferation via miR‑135a‑mediated c‑myc activation.
Wang Y; Hou Z; Li D
Mol Med Rep; 2018 Sep; 18(3):3068-3076. PubMed ID: 30015867
[TBL] [Abstract][Full Text] [Related]
40. Effects of nutraceuticals on anaplastic thyroid cancer cells.
Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
